(TWST) Twist Bioscience - NASDAQ
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 5.688m USD | Total Return: 170.3% in 12m
Avg Turnover: 156M
Qual. Beats: -1
Rev. Trend: 99.7%
Qual. Beats: 3
Warnings
Altman Z'' -3.44 < 1.0 - financial distress zone
Fakeout Extended 3d
Tailwinds
Supp Ema8, Rs Leader, Idiosyncratic Leader, Confidence, Tailwind
Twist Bioscience Corporation is a synthetic biology company that manufactures and sells DNA-based products, including synthetic genes and gene fragments, oligo pools, immunoglobulin G (IgG) proteins, next-generation sequencing (NGS) tools, and methylation detection kits. Its products serve a diverse customer base spanning biotech, pharmaceutical, industrial chemical, and agricultural companies, as well as academic and government research laboratories.
The companys offerings support applications across therapeutics, diagnostics, chemicals and materials, food and agriculture, data storage, and academic research. Twist also supplies synthetic viral reference sequences and research panels, including products targeting SARS-CoV-2, monkeypox, and other respiratory pathogens, and provides precision DNA libraries and antibody optimization tools for drug discovery and development.
Twist maintains a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California. It trades on the NASDAQ under the ticker TWST and went public on October 31, 2018.
- Synbio revenue accelerates as gene synthesis demand rises
- NGS tools margins expand on library prep kit adoption
- Biopharma antibody partnerships drive recurring revenue growth
| Net Income: -81.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA -3.07 > 1.0 |
| NWC/Revenue: 49.69% < 20% (prev 75.78%; Δ -26.09% < -1%) |
| CFO/TA -0.08 > 3% & CFO -55.6m > Net Income -81.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (61.7m) vs 12m ago 3.44% < -2% |
| Gross Margin: 52.07% > 18% (prev 46.70%; Δ 5.37% > 0.5%) |
| Asset Turnover: 64.39% > 50% (prev 58.37%; Δ 6.02% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.30 (Total Current Assets 323.4m - Total Current Liabilities 120.0m) / Total Assets 676.2m |
| B: -2.06 (Retained Earnings -1.39b / Total Assets 676.2m) |
| C: -0.13 (EBIT TTM -80.5m / Avg Total Assets 635.9m) |
| D: 2.06 (Book Value of Equity 455.1m / Total Liabilities 221.1m) |
| Altman-Z'' = -3.44 = D |
| DSRI: 1.09 (Receivables 64.2m/49.9m, Revenue 409.5m/347.7m) |
| GMI: 0.90 (GM 46.70% / 52.07%) |
| AQI: 1.42 (AQ_t 0.25 / AQ_t-1 0.18) |
| SGI: 1.18 (Revenue 409.5m / 347.7m) |
| TATA: -0.04 (NI -81.3m - CFO -55.6m) / TA 676.2m) |
| Beneish M = -2.67 (Cap -4..+1) = A |
As of June 28, 2026, the stock is trading at USD 99.84 with a total of 4,104,153 shares traded. Over the past week, the price has changed by +14.02%, over one month by +53.91%, over three months by +113.56% and over the past year by +170.28%.
Current recommended Stop Loss: 92.60 (which is 7.3% or 1.3 ATR below the current price).
Twist Bioscience has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy TWST.
- StrongBuy: 6
- Buy: 3
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 74.1 | -25.8% |
P/S = 13.892
P/B = 12.4996
Revenue TTM = 409.5m USD
EBIT TTM = -80.5m USD
EBITDA TTM = -56.3m USD
Long Term Debt = 85.4m USD (estimated: total debt 95.8m - short term 10.4m)
Short Term Debt = 10.4m USD (from shortTermDebt, last quarter)
Debt = 95.8m USD (from shortLongTermDebtTotal, last quarter) (leases 95.8m already included)
Net Debt = -75.8m USD (calculated: Debt 95.8m - CCE 171.7m)
Enterprise Value = 5.61b USD (5.69b + Debt 95.8m - CCE 171.7m)
Interest Coverage Ratio = unknown (Ebit TTM -80.5m / Interest Expense TTM 0.0)
EV/FCF = -58.99x (Enterprise Value 5.61b / FCF TTM -95.1m)
FCF Yield = -1.70% (FCF TTM -95.1m / Enterprise Value 5.61b)
FCF Margin = -23.23% (FCF TTM -95.1m / Revenue TTM 409.5m)
Net Margin = -19.85% (Net Income TTM -81.3m / Revenue TTM 409.5m)
Gross Margin = 52.07% ((Revenue TTM 409.5m - Cost of Revenue TTM 196.3m) / Revenue TTM)
Gross Margin QoQ = 51.59% (prev 52.05%)
Tobins Q-Ratio = 8.30 (Enterprise Value 5.61b / Total Assets 676.2m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 95.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -63.6m (EBIT -80.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.70 (Total Current Assets 323.4m / Total Current Liabilities 120.0m)
Debt / Equity = 0.21 (Debt 95.8m / totalStockholderEquity, last quarter 455.1m)
Debt / EBITDA = 1.35 (negative EBITDA) (Net Debt -75.8m / EBITDA -56.3m)
Debt / FCF = 0.80 (negative FCF - burning cash) (Net Debt -75.8m / FCF TTM -95.1m)
Total Stockholder Equity = 465.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.78% (Net Income -81.3m / Total Assets 676.2m)
RoE = -17.46% (Net Income TTM -81.3m / Total Stockholder Equity 465.6m)
RoCE = -14.62% (EBIT -80.5m / Capital Employed (Equity 465.6m + L.T.Debt 85.4m))
RoIC = -11.65% (negative operating profit) (NOPAT -63.6m / Invested Capital 546.2m)
WACC = 12.45% (E(5.69b)/V(5.78b) * Re(12.66%) + D(95.8m)/V(5.78b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 3.19%
[DCF] Fair Price = unknown (Cash Flow -95.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -3.40 | # QB: -1
Revenue Correlation: 99.66 | Revenue CAGR: 22.84% | SUE: 2.05 | # QB: 3
EPS current Quarter (2026-06-30): EPS=-0.18 | Chg30d=N/A | Revisions=N/A | Analysts=2
EPS current Year (2026-09-30): EPS=-0.77 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+63.6% | GrowthRev=+18.6%
EPS next Year (2027-09-30): EPS=-0.76 | Chg30d=+62.77% | Revisions=N/A | GrowthEPS=+0.9% | GrowthRev=+16.1%